Isomorphic Labs has raised a $5 billion series C round, marking the second time in six months that the AI drug development startup has pulled off a multibillion-dollar financing.
London-based Isomorphic emerged in 2021 as a spinoff from DeepMind, a sibling of Google that created AlphaFold to predict protein structures. In May, the startup redefined “big” in private biotech financing by raising a $2.1 billion series B round. Six months later, Isomorphic raised the bar again by reeling in a Brobdingnagian series C round.
Isomorphic has raised the money to fund further development of its drug design engine, IsoDDE, and the pipeline of preclinical programs it has generated. In parallel, the company is investing in translational and clinical development infrastructure to support the progression of programs into human testing.
The biotech’s internal pipeline spans multiple drug modalities and focuses on oncology and immunology. While Isomorphic has yet to provide details of the programs, it has shared evidence that IsoDDE outperforms AlphaFold 3 on a protein-ligand structure prediction benchmark and identifies novel binding sites.
In a statement, Isomorphic President Max Jaderberg, Ph.D., said the company’s machine learning researchers and drug hunters “are routinely solving complex biological problems that have stalled traditional research for decades.”
Isomorphic is still working toward the acid test of showing how drug candidates generated using IsoDDE perform in humans and has yet to disclose detailed preclinical data beyond saying the results are “positive.” While that vacuum leaves room for skepticism, the biotech has persuaded investors to write big checks and landed deals with leading drug developers.
Greenoaks and Sequoia Capital co-led the series C with participation from Andreessen Horowitz and several other new investors. Alphabet, Isomorphic’s parent company, made a significant investment, and all existing investors—Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K. Sovereign AI Fund—returned for the series C.
The financing round cements 2026 as a banner year for a startup that has repeatedly made headlines in its short history. In 2024, Isomorphic disclosed alliances with Eli Lilly and Novartis with a combined value of about $3 billion, including milestones. The biotech raised $600 million in its first external funding round in 2025 and added Johnson & Johnson to its list of partners at the start of 2026.